Stella Xu
Director/Board Member chez DESIGN THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Provenance du réseau au premier degré de Stella Xu
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 13 | |
| Subsidiary | Pharmaceuticals: Major | 13 | |
| Public Company | Pharmaceuticals: Major | 11 | |
| Unknown | 11 | ||
Walking Fish Therapeutics, Inc.
 Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA.
10
| Holding Company | Biotechnology | 10 |
| Venture Capital Fund | Investment Managers | 10 | |
| Holding Company | Pharmaceuticals: Major | 8 | |
Roche Innovation Center
2
| Private Company | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Stella Xu via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Private Equity Investor Chief Tech/Sci/R&D Officer Sales & Marketing | |
| BIOCRYST PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Investment Managers | Chief Executive Officer Director of Finance/CFO | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
| SYNDAX PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| ATRECA, INC. | Biotechnology | Director of Finance/CFO Director/Board Member Director/Board Member | |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member Director/Board Member President Chief Operating Officer | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
| TURG POIN | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chairman Corporate Officer/Principal | |
| SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member Director/Board Member | |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Corporate Officer/Principal Private Equity Investor Chief Executive Officer Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| Stanford University | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | College/University | Doctorate Degree Graduate Degree | |
| The Johns Hopkins University | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| Yale University | College/University | Doctorate Degree Undergraduate Degree Graduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree | |
| University of Bern | College/University | Doctorate Degree Doctorate Degree | |
| AUSPEX PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
| IMMUNE DESIGN CORP | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Chief Operating Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| Haas School of Business | College/University | Undergraduate Degree Masters Business Admin | |
| DERMIRA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| COHERUS BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Balance Therapeutics, Inc.
 Balance Therapeutics, Inc. BiotechnologyHealth Technology Balance Therapeutics, Inc. develops therapeutics to address conditions of intellectual disability. Its pharmacological approach, based on technology licensed from Stanford University, hypothesizes that restoring the proper balance between inhibition and excitation at the neuronal synapse by antagonizing excessive inhibitory circuits could result in the appropriate plasticity for memory and learning to occur in many conditions of intellectual disability. The company was founded by Lyndon Lien, Craig Garner and Daniel Wetmore in 2009 and is headquartered in San Bruno, CA. | Biotechnology | Director of Finance/CFO Director/Board Member | |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Biotechnology | Chairman Director/Board Member | |
| GRITSTONE BIO, INC. | Biotechnology | Chairman Director/Board Member Director/Board Member Founder Director/Board Member | |
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member Founder | |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| ARVINAS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Chief Executive Officer | |
| PASSAGE BIO, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| JASPER THERAPEUTICS, INC. | Director of Finance/CFO Chief Tech/Sci/R&D Officer | ||
SR One Capital Management LP
 SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Investment Managers | Chief Executive Officer Corporate Officer/Principal | |
Electra Therapeutics, Inc.
 Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Star Therapeutics, Inc.
 Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 44 |
| Royaume-Uni | 3 |
| Suisse | 3 |
| France | 2 |
Sectorielle
| Health Technology | 31 |
| Consumer Services | 13 |
| Finance | 4 |
| Commercial Services | 4 |
Opérationnelle
| Director/Board Member | 583 |
| Corporate Officer/Principal | 195 |
| Independent Dir/Board Member | 180 |
| Chairman | 93 |
| Chief Tech/Sci/R&D Officer | 65 |
Relations les plus connectées
| Insiders | |
|---|---|
| Carl Gordon | 59 |
| Pierre Legault | 45 |
| Robert Alexander Ingram | 43 |
| Franklin Berger | 41 |
| Joseph Swedish | 40 |
| Beth Seidenberg | 39 |
| Thomas Woiwode | 39 |
| Elaine Jones | 37 |
| Xiang Ming Cui | 31 |
| Timothy Shannon | 28 |
| Hans-Peter Hasler | 28 |
| Hong Bo Lu | 28 |
| Briggs Morrison | 26 |
| John Schmid | 24 |
| Simeon George | 23 |
